Ocular Inflammatory Reactions following an Inactivated SARS-CoV-2 Vaccine: A Four Case Series

References

• Marian AJ. Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries. Cardiovasc Pathol. Jan - Feb 2021;50:107278. doi:10.1016/j.carpath.2020.107278.
   PubMed Web of Science ®Google Scholar
• Yuce M, Filiztekin E, Ozkaya KG. COVID-19 diagnosis -A review of current methods. Biosens Bioelectron. 2021 Jan 15;172:112752. doi:10.1016/j.bios.2020.112752.
   PubMed Web of Science ®Google Scholar
• Gidengil C, Goetz MB, Newberry S, et al. Safety of vaccines used for routine immunization in the United States: an updated systematic review and meta-analysis. Vaccine. Jun 23 2021;39(28):3696–3716. doi:10.1016/j.vaccine.2021.03.079.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Chetta A, Cazzola M, and Calzetta L. SARS-CoV-2 neutralizing antibodies: a network meta-analysis across vaccines. Vaccines (Basel). Mar 5 2021;9(3):227.
   Web of Science ®Google Scholar
• Soiza RL, Scicluna C, Thomson EC. Efficacy and safety of COVID-19 vaccines in older people. Age Ageing. 2021 Feb 26;50(2):279–283. doi:10.1093/ageing/afaa274.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. Feb 2021;21(2):181–192. doi:10.1016/S1473-3099(20)30843-4.
   PubMed Web of Science ®Google Scholar
• Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA. 2021 Feb 23;325(8):780–781. doi:10.1001/jama.2021.0600.
   PubMed Web of Science ®Google Scholar
• Tarawneh O, Tarawneh H. Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine. Am J Hematol. 2021 May 1;96(5):E133–E134. doi:10.1002/ajh.26106.
   PubMed Web of Science ®Google Scholar
• Banerji A, Wickner PG, Saff R, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract. Apr 2021;9(4):1423–1437. doi:10.1016/j.jaip.2020.12.047.
   PubMed Web of Science ®Google Scholar
• Mitchell OR, Couzins M, Dave R, Bekker J, Brennan PA. COVID-19 vaccination and low cervical lymphadenopathy in the two week neck lump clinic - a follow up audit. Br J Oral Maxillofac Surg. 2021 Jul;59(6):720–721. doi:10.1016/j.bjoms.2021.04.008.
   PubMed Web of Science ®Google Scholar
• Aurich S, Dolle-Bierke S, Francuzik W, et al. Anaphylaxis in elderly patients-data from the European anaphylaxis registry. Front Immunol. 2019;10:750. doi:10.3389/fimmu.2019.00750.
   PubMed Web of Science ®Google Scholar
• Cheng JY, Margo CE. Ocular adverse events following vaccination: overview and update. Surv Ophthalmol. 2022 Mar-Apr;67(2):293–306. doi:10.1016/j.survophthal.2021.04.001.
   PubMed Web of Science ®Google Scholar
• Inagawa S, Onda M, Miyase T, et al. Multiple evanescent white dot syndrome following vaccination for COVID-19: a case report. Medicine (Baltimore). Jan 14 2022;101(2):e28582. doi:10.1097/MD.0000000000028582.
   PubMed Web of Science ®Google Scholar
• Pang K, Pan L, Guo H, Wu X. Case report: associated ocular adverse reactions with inactivated COVID-19 vaccine in China. Front Med (Lausanne). 2021;8:823346. doi:10.3389/fmed.2021.823346.
   PubMed Web of Science ®Google Scholar
• Nanji AA, Fraunfelder FT. Anterior Uveitis following COVID Vaccination: a Summary of Cases from Global Reporting Systems. Ocul Immunol Inflamm. 2022 Feb 28:1–3. doi:10.1080/09273948.2022.2042316.
   Google Scholar
• Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 2021 Mar 16;325(11):1101–1102. doi:10.1001/jama.2021.1967.
   PubMed Web of Science ®Google Scholar
• Pichi F, Aljneibi S, Neri P, Hay S, Dackiw C, Ghazi NG. Association of ocular adverse events with inactivated COVID-19 vaccination in patients in Abu Dhabi. JAMA Ophthalmol. 2021 Oct 1;139(10):1131–1135. doi:10.1001/jamaophthalmol.2021.3477.
   PubMed Web of Science ®Google Scholar
• ElSheikh RH, Haseeb A, Eleiwa TK, Elhusseiny AM. Acute uveitis following COVID-19 Vaccination. Ocul Immunol Inflamm. 2021 Aug 18;29(6):1207–1209. doi:10.1080/09273948.2021.1962917.
   PubMed Web of Science ®Google Scholar
• Pan L, Zhang Y, Cui Y, Wu X. Bilateral uveitis after inoculation with COVID-19 vaccine: a case report. Int J Infect Dis. Dec 2021;113:116–118. doi:10.1016/j.ijid.2021.09.075.
   PubMed Web of Science ®Google Scholar
• Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020 May;20(5):533–534. doi:10.1016/S1473-3099(20)30120-1.
   PubMed Web of Science ®Google Scholar
• Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. Jul 3 2020;369(6499):77–81. doi:10.1126/science.abc1932.
   PubMed Web of Science ®Google Scholar
• Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. Sep 8 2020;324(10):951–960. doi:10.1001/jama.2020.15543.
   PubMed Web of Science ®Google Scholar
• Pu J, Yu Q, Yin Z, et al. The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: a phase I randomized, double-blinded, controlled trial. Vaccine. May 12 2021;39(20):2746–2754. doi:10.1016/j.vaccine.2021.04.006.
   PubMed Web of Science ®Google Scholar
• Klein NP, Ray P, Carpenter D, et al. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine. Jan 22 2010;28(4):1062–1068. doi:10.1016/j.vaccine.2009.10.115.
   PubMed Web of Science ®Google Scholar
• Fraunfelder FW, Suhler EB, Fraunfelder FT. Hepatitis B vaccine and uveitis: an emerging hypothesis suggested by review of 32 case reports. Cutan Ocul Toxicol. 2010 Mar;29(1):26–29. doi:10.3109/15569520903427717.
   PubMed Web of Science ®Google Scholar
• Sham CW, Levinson RD. Uveitis exacerbation after varicella-zoster vaccination in an adult. Arch Ophthalmol. 2012 Jun;130(6):793–794. doi:10.1001/archophthalmol.2011.1881.
   PubMed Web of Science ®Google Scholar
• Holt HD, Hinkle DM, Falk NS, Fraunfelder FT, Fraunfelder FW. Human papilloma virus vaccine associated uveitis. Curr Drug Saf. 2014 Mar;9(1):65–68. doi:10.2174/15748863113086660062.
   PubMedGoogle Scholar
• Kim M. Vogt-Koyanagi-Harada syndrome following influenza vaccination. Indian J Ophthalmol. 2016 Jan;64(1):98. doi:10.4103/0301-4738.178141.
   PubMed Web of Science ®Google Scholar
• Benage M, Fraunfelder FW. Vaccine-associated uveitis. Mo Med. Jan-Feb 2016;113(1):48–52.
   PubMedGoogle Scholar
• Watad A, Quaresma M, Brown S, et al. Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld’s syndrome) - an update. Lupus. Jun 2017;26(7):675–681. doi:10.1177/0961203316686406.
   PubMed Web of Science ®Google Scholar
• Liang Z, Zhu H, Wang X, et al. Adjuvants for coronavirus vaccines. Front Immunol. 2020;11:589833. doi:10.3389/fimmu.2020.589833.
   PubMed Web of Science ®Google Scholar
• Tomljenovic L, Shaw CA. Aluminum vaccine adjuvants: are they safe? Curr Med Chem. 2011;18(17):2630–2637. doi:10.2174/092986711795933740.
   PubMed Web of Science ®Google Scholar
• Ng XL, Betzler BK, Testi I, et al. Ocular adverse events after COVID-19 vaccination. Ocul Immunol Inflamm. Aug 18 2021;29(6):1216–1224. doi:10.1080/09273948.2021.1976221.
   PubMed Web of Science ®Google Scholar
• Koong LR, Chee WK, Toh ZH, Ng XL, Agrawal R, Ho SL. Vogt-Koyanagi-Harada disease associated with COVID-19 mRNA vaccine. Ocul Immunol Inflamm. 2021 Aug 18;29(6):1212–1215. doi:10.1080/09273948.2021.1974492.
   PubMed Web of Science ®Google Scholar
• de Courssou Jb B, Tisseyre M, Hadjadj J, et al. De Novo Vogt-Koyanagi-Harada disease following Covid-19 vaccine: a case report and literature overview. Ocul Immunol Inflamm. Feb 2022;3:1–4.
   Google Scholar
• Kim SY, Kang MS, Kwon HJ. Bilateral Panuveitis Mimicking Vogt-Koyanagi-Harada disease following the first dose of ChAdOx1 nCoV-19 Vaccine. Ocul Immunol Inflamm. Feb 2022;3:1–4.
   Google Scholar
• Chen X, Wang B, Li X. Acute-onset Vogt-Koyanagi-Harada like uveitis following Covid-19 inactivated virus vaccination. Am J Ophthalmol Case Rep. Jun 2022;26:101404. doi:10.1016/j.ajoc.2022.101404.
   PubMedGoogle Scholar
• Chen X, Li X, Li H, Li M, Gong S. Ocular adverse events after inactivated COVID-19 vaccination in Xiamen. Vaccines (Basel). Mar21, 2022;10(3). doi:10.3390/vaccines10030482.
   Web of Science ®Google Scholar